H. Lee Moffitt Cancer Center & Research Institute

Medications

Selinexor for multiple myeloma receives accelerated FDA approval

A first-in-class drug recently granted accelerated approval by the U.S. Food and Drug Administration (FDA) for adult patients with heavily pretreated multiple myeloma has been the subject of study at Moffitt Cancer Center ...

page 7 from 28